Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

Study Overview
=================
Brief Summary
-----------------
Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful. Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans. The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis. The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

Official Title
-----------------
Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

Conditions
-----------------
Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection

Intervention / Treatment
-----------------
* Other: Fluorescein angiography
* Other: Dilated fundus examination
* Biological: Toxoplasmosis serology
* Drug: Anti-toxoplasmosis treatment
* Drug: Anti-inflammatory treatments
* Other: Puncture in anterior chamber


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection Persons affiliated to national social security Exclusion Criteria: Pregnant, parturient or breastfeeding women Persons deprived of liberty by judicial or administrative decision, person under legal protection Refusal by a patient to do the PCA (anterior chamber puncture) Patients whose following will be difficult or nonexistent

Ages Eligible for Study
-----------------
Maximum Age: 18 Years


Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Subjects suspected of toxoplasmosis chorioretinitis infection<br>Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection | Other: Fluorescein angiography<br> <br> Other: Dilated fundus examination<br> <br> Biological: Toxoplasmosis serology<br> <br> Drug: Anti-toxoplasmosis treatment<br> <br> Drug: Anti-inflammatory treatments<br> <br> Other: Puncture in anterior chamber<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ELISA tests | ELISA (enzyme linked immunosorbent assay) tests. Biological markers evaluation : stress protein Hsp70 and antibodies anti-Hsp70. | About an hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Toxoplasmosis, Uveitis, Chorioretinitis, Infection